Academic literature on the topic 'KP1019'
Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles
Consult the lists of relevant articles, books, theses, conference reports, and other scholarly sources on the topic 'KP1019.'
Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.
You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.
Journal articles on the topic "KP1019"
Alessio, Enzo, and Luigi Messori. "NAMI-A and KP1019/1339, Two Iconic Ruthenium Anticancer Drug Candidates Face-to-Face: A Case Story in Medicinal Inorganic Chemistry." Molecules 24, no. 10 (May 24, 2019): 1995. http://dx.doi.org/10.3390/molecules24101995.
Full textHeffeter, Petra, Katharina Böck, Bihter Atil, Mir Ali Reza Hoda, Wilfried Körner, Caroline Bartel, Ute Jungwirth, et al. "Intracellular protein binding patterns of the anticancer ruthenium drugs KP1019 and KP1339." JBIC Journal of Biological Inorganic Chemistry 15, no. 5 (March 11, 2010): 737–48. http://dx.doi.org/10.1007/s00775-010-0642-1.
Full textStultz, Laura K., Alexandra Hunsucker, Sydney Middleton, Evan Grovenstein, Jacob O’Leary, Eliot Blatt, Mary Miller, James Mobley, and Pamela K. Hanson. "Proteomic analysis of the S. cerevisiae response to the anticancer ruthenium complex KP1019." Metallomics 12, no. 6 (2020): 876–90. http://dx.doi.org/10.1039/d0mt00008f.
Full textBergamo, A., A. Masi, M. A. Jakupec, B. K. Keppler, and G. Sava. "Inhibitory Effects of the Ruthenium Complex KP1019 in Models of Mammary Cancer Cell Migration and Invasion." Metal-Based Drugs 2009 (September 17, 2009): 1–9. http://dx.doi.org/10.1155/2009/681270.
Full textKuhn, P. S., V. Pichler, A. Roller, M. Hejl, M. A. Jakupec, W. Kandioller, and B. K. Keppler. "Improved reaction conditions for the synthesis of new NKP-1339 derivatives and preliminary investigations on their anticancer potential." Dalton Transactions 44, no. 2 (2015): 659–68. http://dx.doi.org/10.1039/c4dt01645a.
Full textCirri, Damiano, Tiziano Marzo, Iogann Tolbatov, Alessandro Marrone, Francesco Saladini, Ilaria Vicenti, Filippo Dragoni, Adele Boccuto, and Luigi Messori. "In Vitro Anti-SARS-CoV-2 Activity of Selected Metal Compounds and Potential Molecular Basis for Their Actions Based on Computational Study." Biomolecules 11, no. 12 (December 10, 2021): 1858. http://dx.doi.org/10.3390/biom11121858.
Full textLevina, Aviva, Anthony R. M. Chetcuti, and Peter A. Lay. "Controversial Role of Transferrin in the Transport of Ruthenium Anticancer Drugs." Biomolecules 12, no. 9 (September 18, 2022): 1319. http://dx.doi.org/10.3390/biom12091319.
Full textJuszczak, Michał, Magdalena Kluska, Daniel Wysokiński, and Katarzyna Woźniak. "Anti-cancer properties of ruthenium compounds: NAMI-A and KP1019." Postępy Higieny i Medycyny Doświadczalnej 74 (February 19, 2020): 12–19. http://dx.doi.org/10.5604/01.3001.0013.8549.
Full textGransbury, Gemma K., Peter Kappen, Chris J. Glover, James N. Hughes, Aviva Levina, Peter A. Lay, Ian F. Musgrave, and Hugh H. Harris. "Comparison of KP1019 and NAMI-A in tumour-mimetic environments." Metallomics 8, no. 8 (2016): 762–73. http://dx.doi.org/10.1039/c6mt00145a.
Full textHeffeter, P., M. A. Jakupec, M. Pongratz, P. Chiba, M. Micksche, W. Körner, M. Hauses, B. Marian, B. K. Keppler, and W. Berger. "630 Molecular mechanisms of resistance against the ruthenium compound KP1019." European Journal of Cancer Supplements 2, no. 8 (September 2004): 190–91. http://dx.doi.org/10.1016/s1359-6349(04)80638-4.
Full textDissertations / Theses on the topic "KP1019"
O'Riley, Hannah Adele. "Mechanisms of the Anti-Metastatic and Cytotoxic Properties of Ruthenium Anti-Cancer Drugs." Thesis, The University of Sydney, 2015. http://hdl.handle.net/2123/13881.
Full textThomé, Isis Pires. "Síntese, caracterização e avaliação da atividade citotóxica de Indazolium trans[tetrachlorobis (1H-indazole) ruthenate (III)] (KP1019) em células de carcinoma mamário." reponame:Repositório Institucional da UnB, 2016. http://repositorio.unb.br/handle/10482/21255.
Full textSubmitted by Fernanda Percia França (fernandafranca@bce.unb.br) on 2016-07-15T13:21:44Z No. of bitstreams: 1 2016_IsisPiresThomé.pdf: 1759165 bytes, checksum: 802581531ad1c8049db8b4a6e5545850 (MD5)
Approved for entry into archive by Raquel Viana(raquelviana@bce.unb.br) on 2016-08-19T11:51:16Z (GMT) No. of bitstreams: 1 2016_IsisPiresThomé.pdf: 1759165 bytes, checksum: 802581531ad1c8049db8b4a6e5545850 (MD5)
Made available in DSpace on 2016-08-19T11:51:16Z (GMT). No. of bitstreams: 1 2016_IsisPiresThomé.pdf: 1759165 bytes, checksum: 802581531ad1c8049db8b4a6e5545850 (MD5)
O câncer é uma doença muito agressiva que atinge milhões de pessoas no mundo. Entre os vários tipos de câncer, o carcinoma mamário é o segundo mais frequente no mundo e o que mais acomete as mulheres. A quimioterapia é uma abordagem terapêutica bastante empregada, especialmente no caso de doença metastática. Contudo, este tipo de tratamento apresenta limitações como falta de especificidade às células tumorais e ocorrência de quimioresistência. Por isso, faz-se necessário o desenvolvimento de tratamentos mais eficazes contra esta doença. Com o objetivo de melhorar a eficácia da quimioterapia para aumentar a expectativa de vida dos pacientes, várias propostas têm sido sugeridas. Os complexos metálicos vêm se mostrando agentes antitumorais promissores. Dentre eles, os complexos de Rutênio (Ru), como o KP1019, têm se destacado, pois apresentam (1) capacidade em se ligar à biomoléculas como transferrina; (2) considerável labilidade química; (3) atuação em células que desenvolveram resistência à cisplatina e (4) capacidade em participar de reações de oxirredução permitindo a existência dos mais importantes estados de oxidação em meio biológico. No presente trabalho, foi realizada a síntese do KP1019 e sua caracterização por ressonância magnética nuclear (RMN). Além disso, avaliou-se o efeito citotóxico deste complexo em células murinas de carcinoma mamário (4T1) e normais de fibroblastos (NIH-3T3). A citotoxicidade do KP1019 foi avaliada por testes de viabilidade celular por meio do método colorimétrico de MTT. As células foram tratadas com doses que variaram de 1,25 a 200 μM de KP1019 e cisplatina por períodos de 24, 48 e 72 horas. O KP1019 foi sintetizado e depois caracterizado por RMN e avaliado quanto à sua toxicidade. Após 24 h de tratamento, KP1019 induziu citotoxicidade semelhante à cisplatina em ambas as linhagens celulares. Além disso, notou-se que as linhagens 4T1 e NIH-3T3 tiveram a mesma sensibilidade ao tratamento com KP1019. No período de 48 horas, o KP1019 induziu diferente citotoxicidade nas duas linhagens, sendo que este não apresentou citotoxicidade para 4T1, enquanto que a cisplatina foi mais citotóxica para esta linhagem (doses acima de 12,5 μM). Em contrapartida, o KP1019 foi mais citotóxico para NIH-3T3 em doses a partir de 25 μM. Já no período de 72 horas, ambos os complexos foram similarmente citotóxicos em ambas as linhagens celulares a partir das doses 12,5 μM. Além disso, o efeito citotóxico de KP1019 e cisplatina foram diferentes na linhagem 4T1 (doses 1,25 e 2,5 μM). Ademais, a morfologia das células 4T1 foi analisada em microscópio óptico após tratamento por 24 horas com 20 μM de KP1019 ou cisplatina (IC50) e observou-se várias alterações relacionadas à citotoxicidade como arredondamento das células e aumento na quantidade de vesículas citoplasmáticas. Dessa forma, sugere-se que o efeito citotóxico de KP1019 foi dependente da dose, linhagem celular e tempo avaliados e, esta citotoxicidade está associada a alterações morfológicas provenientes de processo de morte celular, o que reforça o excelente potencial de KP1019 para uso na quimioterapia do câncer de mama. ________________________________________________________________________________________________ ABSTRACT
Cancer is a very aggressive disease that affects millions of people worldwide. Among the various types of cancer, breast cancer is the second most frequent in the world and that most affects women. Chemotherapy is fairly a therapeutic approach employed, particularly for metastatic disease. However, this treatment has limitations such as lack of specificity for tumor cells and occurrence of chemoresistance. Therefore, it is necessary to develop more effective treatments for this disease. In order to improve the effectiveness of chemotherapy to increase the life expectancy of patients, various proposals have been suggested. The metal complexes have shown to be promising antitumor agents. Among them, the complexes of ruthenium (Ru) as the KP1019, have been highlighted as present (1) the ability to bind to biomolecules such as transferrin; (2) substantial chemical lability; (3) operating in cells that have developed resistance to cisplatin and (4) the ability to participate in redox reactions allowing the existence of the most important oxidation states in biological medium. In the present work, the synthesis of KP1019 and its characterization by nuclear magnetic resonance imaging was performed (NMR). In addition, it evaluated the cytotoxic effect of this complex on murine mammary carcinoma cells (4T1) and normal fibroblasts (NIH-3T3). The cytotoxicity of KP1019 was evaluated by cell viability tests using the MTT colorimetric method. Cells were treated with doses ranging from 1.25 to 200 mM of KP1019 and cisplatin for periods of 24, 48 and 72 hours. The KP1019 was synthesized and then characterized by NMR and evaluated for their toxicity. After 24 h of treatment, KP1019 induced cytotoxicity similar to cisplatin in both cell lines. Furthermore, it was observed that the 4T1 and NIH-3T3 lines showed the same sensitivity to treatment with KP1019. Within 48 hours, the KP1019 induced cytotoxicity in two different strains, and this showed no cytotoxicity for 4T1, while cisplatin was more cytotoxic to this strain (over 12.5 uM doses). In contrast, KP1019 was more cytotoxic to NIH-3T3 at doses from 25 uM. In the 72-hour period, both complexes were cytotoxic similar in both cell lines from 12.5 uM doses. Additionally, the cytotoxic effect of cisplatin were KP1019 and different in lineage 4T1 (doses 1.25 and 2.5 uM). Furthermore, the morphology of 4T1 cells was examined under an optical microscope after treatment for 24 hours with 20 uM of KP1019 or cisplatin (IC50) and observed several changes related to cytotoxicity and rounding of the cells and increasing the amount of cytoplasmic vesicles. Thus, it is suggested that the cytotoxic effect of KP1019 was dose-dependent cell line and evaluated time and this cytotoxicity is associated with morphologic changes from cell death process, which enhances the excellent potential KP1019 for use in cancer chemotherapy breast cancer.
Wedding, Jason Lee. "Application of Synchrotron-Based Spectroscopic Techniques XAS and XFM Towards Probing the Cellular Metallome." Thesis, 2019. http://hdl.handle.net/2440/120496.
Full textThesis (Ph.D.) -- University of Adelaide, School of Physical Sciences, 2019
Books on the topic "KP1019"
Directory of European Agricultural Organizations/Kp109. Unipub, 1985.
Find full textDirectory of European Agricultural Organizations/Kp109. Unipub, 1985.
Find full textImproving Venture Capital Opportunities in Europe/Kp108. Kogan Page Ltd, 1985.
Find full textLovasz, J. Incentives for Industrial Research, Development and Innovation/Kp107. Kogan Page Ltd, 1986.
Find full textMicad '85: Proceedings of the 4th European Conference on Cad/Cam and Computer Graphics/Kp105. Unipub, 1985.
Find full textBook chapters on the topic "KP1019"
"5. THE DECEPTIVELY SIMILAR RUTHENIUM(III) DRUG CANDIDATES KP1019 AND NAMI-A HAVE DIFFERENT ACTIONS. WHAT DID WE LEARN IN THE PAST 30 YEARS?" In Metallo-Drugs: Development and Action of Anticancer Agents, 141–70. De Gruyter, 2018. http://dx.doi.org/10.1515/9783110470734-005.
Full textConference papers on the topic "KP1019"
Lukianova, Anna A., Peter V. Evseev, Mikhail M. Shneider, Ekaterina A. Gornostal, Yulia Mikhaylova, Andrey Shelenkov, and Konstantin A. Miroshnikov. "Pre-Treatment With Polysaccharide Depolymerase Enhances the Infective Performance of Klebsiella Phage KP1079." In 2022 Ural-Siberian Conference on Computational Technologies in Cognitive Science, Genomics and Biomedicine (CSGB). IEEE, 2022. http://dx.doi.org/10.1109/csgb56354.2022.9865515.
Full textAlte, Beatrix, Christine Pirker, Thomas Mohr, Kushtrim Kryeziu, Bernhard K. Keppler, Petra Heffeter, and Walter Berger. "Abstract 2573: Investigation of factors involved in the hypersensitivity to KP1339-treatment." In Proceedings: AACR 106th Annual Meeting 2015; April 18-22, 2015; Philadelphia, PA. American Association for Cancer Research, 2015. http://dx.doi.org/10.1158/1538-7445.am2015-2573.
Full textBaier, Dina Salome, Beatrix Schoenhacker-Alte, Christine Pirker, Bernhard Englinger, Thomas Mohr, Samuel Meier-Menches, Clemens Roehrl, et al. "Abstract 1839: Lipid metabolism as target and modulator of KP1339 anticancer activity." In Proceedings: AACR Annual Meeting 2020; April 27-28, 2020 and June 22-24, 2020; Philadelphia, PA. American Association for Cancer Research, 2020. http://dx.doi.org/10.1158/1538-7445.am2020-1839.
Full textHeffeter, Petra, Bihter Atil, Ute Jungwirth, Wilfried Koerner, Michael Micksche, Bernhard K. Keppler, and Walter Berger. "Abstract C103:In vitroandin vivoanticancer activity of the new ruthenium compound KP1339 against human liver cancer models." In Abstracts: AACR-NCI-EORTC International Conference: Molecular Targets and Cancer Therapeutics--Nov 15-19, 2009; Boston, MA. American Association for Cancer Research, 2009. http://dx.doi.org/10.1158/1535-7163.targ-09-c103.
Full textHeffeter, Petra, Bihter Atil, Kushtrim Kryeziu, Ute Jungwirth, Elisabeth Gal, Bernhard K. Keppler, and Walter Berger. "Abstract 3541: Combination of the ruthenium compound KP1339 with the tyrosine kinase inhibitor sorafenib: A promising approach for the treatment of human hepatoma." In Proceedings: AACR 102nd Annual Meeting 2011‐‐ Apr 2‐6, 2011; Orlando, FL. American Association for Cancer Research, 2011. http://dx.doi.org/10.1158/1538-7445.am2011-3541.
Full textReports on the topic "KP1019"
Smith, S. L., L. P. Roy, A. G. Lewkowicz, and J. Chartrand. Ground thermal data collection along the Alaska Highway corridor (KP1559-1895), Yukon, summer 2016. Natural Resources Canada/ESS/Scientific and Technical Publishing Services, 2017. http://dx.doi.org/10.4095/306304.
Full textSmith, S. L., M. Ednie, and J. Chartrand. Ground thermal data collection along the Alaska Highway corridor (KP1559-1895), Yukon, summer 2015. Natural Resources Canada/ESS/Scientific and Technical Publishing Services, 2016. http://dx.doi.org/10.4095/298769.
Full text